Composition comprising perilla frutescens complex for improving eye health, and use thereof

Abstract

The present invention relates to a composition comprising a Perilla frutescens complex for improving eye health, and a use thereof. The composition for preventing or treating retinal diseases or improving eye health, according to one embodiment of the present invention, comprising a Perilla frutescens extract, and further comprising either Rosa hybrida extract or a Mentha piperita extract, has few side effects by being based on natural material ingredients, is easily accessible, and is economical while exhibiting excellent eye health improvement effects, and thus can be effectively used for the prevention, treatment or alleviation of retinal diseases and the improvement of eye health.

Description

Composition for improving eye health containing a perilla complex and the use thereof

[0001] The present invention relates to a composition for improving eye health comprising a perilla plant compound and the use thereof.

[0002] This invention was supported by the Gyeonggi Regional Cooperation Research Center, Gyeonggi Regional Cooperation Research Center (GRRC) Project: Research Center for Technologies to Respond to Unovercome Diseases in Aging (Project No.: GRRCAjou2023-B01) (Research period: July 1, 2023 – June 30, 2029; Implementing agency: Ajou University Industry-Academic Cooperation Foundation).

[0003] The eyes are the body's core sensory organs that receive most of the information from the external world; almost all human activities depend heavily on vision, and clear eyesight is a key factor determining the quality of life. At the heart of eye function are the retina, which detects light, and the optic nerve, which transmits detected information to the brain; maintaining the health of these two components is essential for preserving clear vision. However, the retina and optic nerve are neural tissues that are extremely difficult to fully recover once damaged, and such damage can lead directly to permanent vision loss, requiring special care. In modern society, however, the risk of damage to the retina and optic nerve is increasing due not only to the rapid surge in the use of digital devices such as smartphones and computers, but also to the aging population, changes in lifestyle habits, and the rise in various harmful external factors like fine dust. Consequently, the risk of eye diseases is also increasing.

[0004] Glaucoma, a representative optic nerve damage disorder among these conditions, is one of the leading causes of blindness worldwide. It is a progressive disease in which the optic nerve is gradually damaged due to various risk factors, primarily elevated intraocular pressure, leading to a progressive narrowing of the visual field and eventually blindness. There are no distinct symptoms in the early stages, so early diagnosis and consistent lifelong management are crucial for the prognosis. Since the optic nerve acts as a bridge transmitting visual information received from the retina to the brain, damage caused by glaucoma blocks the visual information transmission pathway itself, resulting in irreversible vision loss.

[0005] Retinal diseases are also closely linked to optic nerve function. Among retinal diseases, macular degeneration is one of the leading causes of blindness in the elderly, occurring as the macula—the part of the retina responsible for central vision—gradually degenerates. This leads to a significant decline in central vision, causing symptoms such as distorted text or straight lines, resulting in severe difficulties in daily life. Additionally, diabetic retinopathy, a major complication of diabetes, damages the microvessels of the retina, causing hemorrhage and edema. Furthermore, retinal vascular occlusion, which can cause sudden vision loss; retinal detachment, which results in visual field defects; and retinitis pigmentosa, in which photoreceptor cells are progressively destroyed due to genetic factors, can leave behind permanent visual impairment once they develop.

[0006] As such, optic nerve damage diseases, including glaucoma, and major retinal diseases are all progressive, and achieving complete functional recovery of damaged nerve tissue is extremely difficult with current medical technology. Current glaucoma treatment primarily focuses on lowering intraocular pressure to slow the progression of optic nerve damage, utilizing medication, laser therapy, and surgical methods. Similarly, for retinal diseases such as macular degeneration or diabetic retinopathy, the main treatment goal is to suppress disease exacerbation through intravitreal drug injections and laser therapy. However, these treatments offer little in the way of fundamental neuroprotection or regenerative effects, and the need for long-term management and repeated treatments significantly impacts the quality of life. Therefore, there is a pressing need to discover and develop safe, functional materials derived from natural products that can effectively contribute to the prevention and management of diseases characterized by progressive optic nerve damage, such as glaucoma, as well as related retinal diseases.

[0007] Perilla frutescens, also known as shiso, is an annual plant belonging to the Lamiaceae family. Due to its distinctive aroma and color, it has been widely used for both culinary and medicinal purposes since ancient times. In Korea, the leaves and seeds are used as food ingredients, and in traditional Korean medicine, it is known for its antipyretic, analgesic, anti-inflammatory, and anti-allergic properties, and has been used to treat colds, coughs, and indigestion.

[0008] Korean Registered Patent No. 10-2171589 relates to a composition for improving cognitive or memory ability and the use thereof, and discloses that the composition contains a fermented extract of perilla leaves and that consuming it has an effect on cognitive or memory ability. However, there have been no studies or reports to date regarding the eye health improvement effect of a composition in which perilla extract is mixed with other natural products.

[0009] Under the circumstances described above, the inventors confirmed the eye health improvement effects of various natural extracts and selected natural extracts that exhibited significant optic nerve protective effects. Furthermore, by testing the eye health improvement effects of a mixture of the selected extracts and confirming that a synergistic effect was observed in the mixture compared to a single extract, the present invention was completed.

[0010] Accordingly, the object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of retinal disease comprising a Perilla frutescens extract and additionally comprising either a Rosa hybrida extract or a Mentha piperita extract.

[0011] Another objective of the present invention is to provide a health functional food composition for the prevention or improvement of retinal diseases, comprising Perilla frutescens extract and additionally comprising either Rosa hybrida extract or Mentha piperita extract.

[0012] Another objective of the present invention is to provide a food composition for improving eye health comprising Perilla frutescens extract and additionally comprising either Rosa hybrida extract or Mentha piperita extract.

[0013] Another objective of the present invention is to provide a food additive for improving eye health comprising Perilla frutescens extract and additionally comprising either Rosa hybrida extract or Mentha piperita extract.

[0014] Another objective of the present invention is to provide a quasi-drug composition for improving eye health, comprising Perilla frutescens extract and additionally comprising either Rosa hybrida extract or Mentha piperita extract.

[0015] Another objective of the present invention is to provide a feed composition for improving eye health comprising Perilla frutescens extract and additionally comprising either Rosa hybrida extract or Mentha piperita extract.

[0016] The terms used in this specification are for descriptive purposes only and should not be interpreted as being limiting. Singular expressions include plural expressions unless the context clearly indicates otherwise. In this specification, terms such as "comprising" or "having" are intended to indicate the existence of the features, numbers, steps, actions, components, or combinations thereof described in the specification, and should be understood as not precluding the existence or addition of one or more other features, numbers, steps, actions, components, or combinations thereof.

[0017] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as generally understood by those skilled in the art to which the embodiments pertain. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and should not be interpreted in an ideal or overly formal sense unless explicitly defined in this application.

[0018] The present invention will be described in detail below.

[0019]

[0020] To achieve the above-mentioned objective, one aspect of the present invention provides a pharmaceutical composition for the prevention or treatment of retinal disease, comprising a Perilla frutescens extract and further comprising either a Rosa hybrida extract or a Mentha piperita extract.

[0021] In one embodiment of the present invention, the extraction solvent may be water, alcohol, or a mixture thereof. The alcohol may be a C1 to C4 lower alcohol, and the lower alcohol may be 30% ethanol, 50% ethanol, 70% ethanol, or methanol.

[0022] In one embodiment of the present invention, the extract may be obtained by hot water extraction at a temperature of 70 to 90°C, and more specifically, may be performed under temperature conditions of 75 to 90°C, 75 to 80°C, 70 to 85°C, or 70 to 80°C, 80 to 90°C, most preferably 75 to 85°C, but is not limited thereto.

[0023] In addition, the perilla extract, rose extract, and peppermint extract of the present invention may comprise any one of an extract obtained by extraction treatment of perilla, rose, or peppermint, a diluted or concentrated extract, a dried product obtained by drying the extract, or a modified or purified product thereof.

[0024] In one embodiment of the present invention, the composition may be a mixture of perilla extract: rose extract or perilla extract: peppermint extract in an appropriate weight ratio. It may be obtained by mixing perilla, rose, or peppermint in their respective weight ratios and extracting them simultaneously using the extraction method described above, or by mixing the respective perilla extract, rose extract, and peppermint extract obtained by the extraction method described above in their corresponding weight ratios. Within the above range of mixing ratios, the effect of improving eye health, including retinal diseases, may be superior to that of a single extract.

[0025] In one embodiment of the present invention, the perilla extract: rose extract or perilla extract: peppermint extract may be mixed in a weight ratio of 1:0.1~10, 1:0.1~8, 1:0.3~8, 1:0.3~5, or 1:0.5~3, preferably in a weight ratio of 1:0.1~3, 1:0.1~1.5, or 1:0.1~2, and most preferably in a weight ratio of 1:0.1~1, but is not limited thereto.

[0026] The term "prevention" as used in this invention refers to any act that causes the symptoms of retinal disease to be suppressed or its onset to be delayed due to the composition of this invention.

[0027] In one embodiment of the present invention, the prevention, improvement, or treatment of the retinal disease may exhibit an antioxidant effect or a protective effect on optic nerve cells. In one embodiment of the present invention, cell viability was tested for Perilla frutescens extract, rose extract, and peppermint extract, or a mixture thereof, using a DPPH radical scavenging assay or an MTT assay. As a result, it was confirmed that they exhibited an antioxidant effect compared to the control group and that the optic nerve cell viability significantly increased.

[0028] In one embodiment of the present invention, the retinal disease may be one or more selected from the group consisting of glaucoma, macular degeneration, retinal vascular occlusion, macular hole, diabetic retinopathy, retinal detachment, central serous retinopathy, night blindness, retinitis pigmentosa, epiretinal membrane, retinitis pigmentosa, optic neuropathy, and retinopathy.

[0029] The pharmaceutical composition of the present invention may be in various oral or parenteral formulations. When formulating the composition, it may be prepared using one or more buffers (e.g., saline solution or PBS), antioxidants, bacteriostatic agents, chelating agents (e.g., EDTA or glutathione), fillers, extenders, binders, adjuvants (e.g., aluminum hydroxide), suspending agents, thickening agents, wetting agents, disintegrants or surfactants, diluents or excipients.

[0030] Solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid dosage forms are prepared by mixing at least one excipient with one or more compounds, for example, starch (including corn starch, wheat starch, rice starch, potato starch, etc.), calcium carbonate, sucrose, lactose, dextrose, sorbitol, mannitol, xylitol, erythritol, maltitol, cellulose, methyl cellulose, sodium carboxymethylcellulose and hydroxypropylmethylcellulose, or gelatin, etc. For example, tablets or sugar-coated tablets can be obtained by combining an active ingredient with a solid excipient, grinding the mixture, adding a suitable auxiliary agent, and processing it into a granular mixture.

[0031] In addition, lubricants such as magnesium stearate and talc are also used in addition to simple excipients. Liquid formulations for oral administration include suspensions, liquid formulations, emulsions, or syrups, and may contain various excipients, such as humectants, sweeteners, flavorings, or preservatives, in addition to commonly used simple diluents like water and liquid paraffin. Additionally, cross-linked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may be added as disintegrants, and may additionally include anticoagulants, flavorings, emulsifiers, solubilizers, dispersants, flavorings, antioxidants, packaging agents, pigments, and preservatives.

[0032] Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, or suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspensions. Witepsol, macrogol, Tween 61, cocoa paste, laurin paste, glycerol, gelatin, etc. may be used as bases for suppositories.

[0033] The composition of the present invention may be administered orally or parenterally, and when administered parenterally, it may be formulated according to methods known in the art in the form of a topical application; an injectable; a transdermal application; or a nasal inhalant.

[0034] The above-mentioned injectable must be sterilized and protected from contamination by microorganisms such as bacteria and fungi. Suitable carriers for the injectable may include, but are not limited to, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), mixtures thereof, and / or vegetable oils, as solvents or dispersion media. More preferably, suitable carriers may include Hanks' solution, Ringer's solution, PBS (phosphate buffered saline) containing triethanolamine, sterile water for injection, isotonic solutions such as 10% ethanol, 40% propylene glycol, and 5% dextrose. To protect the injectable from microbial contamination, various antimicrobial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, and thimerosal may be additionally included. Additionally, the injectable may, in most cases, further include isotonic agents such as sugars or sodium chloride.

[0035] In the case of an inhalation dose, the compound used according to the present invention can be conveniently delivered in the form of an aerosol spray from a pressurized pack or atomizer using a suitable propellant, for example, dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve that delivers a metered amount. For example, gelatin capsules and cartridges used in an inhaler or blower can be formulated to contain the compound and a powder mixture of a suitable powder base, such as lactose or starch.

[0036] The composition of the present invention is administered in a pharmaceutically effective amount. A pharmaceutically effective amount refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level may be determined based on factors including the type and severity of the patient's disease, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. That is, the total effective amount of the composition of the present invention may be administered to the patient as a single dose, or administered via a fractionated treatment protocol involving long-term administration of multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects by considering all the aforementioned factors, and this can be easily determined by a person skilled in the art.

[0037] The dosage of the pharmaceutical composition of the present invention varies depending on the patient's weight, age, gender, health status, diet, time of administration, method of administration, excretion rate, and severity of the disease. It may be increased or decreased depending on the route of administration, severity of obesity, gender, weight, age, etc.

[0038] The composition of the present invention can be used alone or in combination with methods using chemotherapy and biological response modifiers.

[0039]

[0040] Another aspect of the present invention provides a health functional food composition for the prevention or improvement of retinal diseases, comprising a Perilla frutescens extract and additionally comprising either a Rosa hybrida extract or a Mentha piperita extract.

[0041] The term "improvement" as used in the present invention refers to any action that at least reduces parameters related to the condition being treated, such as the degree of symptoms.

[0042] The term "food" used in the present invention includes meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, vitamin complexes, health functional foods, and health foods, and includes all foods in the conventional sense.

[0043] Since the food composition of the present invention can be consumed on a daily basis, it can be expected to have an effect of improving eye health, including retinal diseases, and thus can be very usefully used for health promotion purposes.

[0044] The above-mentioned functional food is synonymous with food for special health use (FosHU) and refers to a food with high medical or therapeutic effects that is processed to efficiently exhibit bio-regulatory functions in addition to nutritional supply. Here, "functionality" means obtaining useful effects for health purposes, such as regulating nutrients or physiological actions regarding the structure and function of the human body. The food of the present invention can be manufactured by methods commonly used in the industry, and during such manufacturing, raw materials and ingredients commonly added in the industry may be added. Furthermore, the formulation of the food can be manufactured without restriction as long as it is a formulation recognized as a food. The food composition of the present invention can be manufactured in various forms of formulations. Unlike general pharmaceuticals, it uses food as a raw material, offering the advantage of not causing side effects that may occur with long-term use of pharmaceuticals. Additionally, due to its excellent portability, the food of the present invention can be consumed as an adjuvant to enhance the effect of improving eye health, including retinal diseases.

[0045] The aforementioned "health food" refers to food that has active effects in maintaining or promoting health compared to general food, and "health supplement food" refers to food intended for the purpose of supporting health. In some cases, the terms health functional food, health food, and health supplement food are used interchangeably.

[0046] Specifically, the above-mentioned health functional food is a food prepared by adding the compound of the present invention to food materials such as beverages, teas, spices, chewing gum, and confectionery, or by encapsulating, powdering, or suspension, and means that consuming it brings about specific health effects. Unlike general medicines, it has the advantage of not having side effects that may occur when taking medicine for a long period of time because it is made from food.

[0047] The above food composition may further include a physiologically acceptable carrier, the type of carrier is not particularly limited, and any carrier commonly used in the relevant technical field may be used.

[0048] In addition, the above food composition may include additional ingredients that are commonly used in food compositions to improve odor, taste, visual appearance, etc. For example, it may include vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, pantothenic acid, etc. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), and chromium (Cr); and amino acids such as lysine, tryptophan, cysteine, and valine.

[0049] In addition, the above food composition may include food additives such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), disinfectants (bleaching powder and high-grade bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), etc.), coloring agents (tar dyes, etc.), colorants (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite), seasonings (MSG, monosodium glutamate, etc.), sweeteners (dulcin, cyclamate, saccharin, sodium, etc.), flavorings (vanillin, lactones, etc.), leavening agents (alum, potassium hydrogen tartrate, etc.), reinforcing agents, emulsifiers, thickeners (sizing agents), coating agents, gum bases, antifoaming agents, solvents, and improvers. The above additives can be selected according to the type of food and used in appropriate amounts.

[0050] As an example of the food composition of the present invention, it may be used as a health drink composition, in which case it may contain various flavoring agents or natural carbohydrates as additional ingredients, as in conventional beverages. The natural carbohydrates described above may be monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; and sugar alcohols such as xylitol, sorbitol, and erythritol. Sweeteners may include natural sweeteners such as thaumatin and stevia extract; and synthetic sweeteners such as saccharin and aspartame. The proportion of the natural carbohydrates may generally be about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g, per 100 mL of the health drink composition of the present invention.

[0051] In addition to the above, the health drink composition may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, or carbonating agents. Furthermore, it may contain fruit pulp for the production of natural fruit juices, fruit juice beverages, or vegetable beverages. These ingredients may be used independently or in combination. Although the proportion of these additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health drink composition of the present invention.

[0052]

[0053] Another aspect of the present invention provides a food composition for improving eye health comprising Perilla frutescens extract and additionally comprising either Rosa hybrida extract or Mentha piperita extract.

[0054]

[0055] Another aspect of the present invention provides a food additive for improving eye health comprising a Perilla frutescens extract and additionally comprising either a Rosa hybrida extract or a Mentha piperita extract.

[0056] The term "food additive" as used in the present invention refers to a component that can be added to food as an auxiliary component, and can be appropriately selected and used by a person skilled in the art as it is added to the manufacture of food of each formulation. Examples of food additives include various nutritional supplements, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc., but the types of food additives of the present invention are not limited by the above examples.

[0057]

[0058] Another aspect of the present invention provides a quasi-drug composition for improving eye health, comprising Perilla frutescens extract and additionally comprising either Rosa hybrida extract or Mentha piperita extract.

[0059] The composition of the quasi-drug of the present invention refers to articles used for the purpose of diagnosing, treating, improving, alleviating, managing, or preventing diseases of humans or animals, among which the effect is milder than that of pharmaceuticals. For example, according to the Pharmaceutical Affairs Act, quasi-drugs are defined as articles excluding those used for pharmaceutical purposes, and include products used for the treatment or prevention of diseases of humans or animals, products that have a mild effect on the human body or do not act directly on it, etc.

[0060] In one embodiment of the present invention, when used as a quasi-drug composition, the composition may be added as is or used together with other quasi-drug ingredients, and may be used appropriately according to conventional methods. The mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health, or therapeutic treatment).

[0061]

[0062] Another aspect of the present invention provides a feed composition for improving eye health, comprising a Perilla frutescens extract and additionally comprising either a Rosa hybrida extract or a Mentha piperita extract.

[0063] As used in the present invention, the term "feed" refers to any natural or artificial prescribed food, single meal, etc., or the components of said single meal, intended for or suitable for animals to eat, consume, and digest.

[0064] The types of the above feed are not particularly limited, and feeds commonly used in the relevant technical field may be used. Non-limiting examples of the above feed include plant-based feeds such as grains, root vegetables, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, meal, or grain by-products; and animal-based feeds such as proteins, inorganic substances, oils and fats, minerals, oils and fats, single-cell proteins, zooplankton, or food waste. These may be used individually or in a mixture of two or more types.

[0065] A composition for the prevention or treatment of retinal diseases or for improving eye health, comprising a Perilla frutescens extract according to one embodiment of the present invention and additionally comprising either a Rosa hybrida extract or a Mentha piperita extract, is based on natural materials, has few side effects, is accessible, and is economical, and has excellent eye health improvement effects; therefore, it can be usefully utilized for the prevention, treatment, or improvement of retinal diseases and for improving eye health.

[0066] Figure 1 shows the results of analyzing the DPPH radical scavenging activity of six types of natural extracts (yarrow, rose, perilla, chamomile, peppermint, Korean mint, etc.) at different concentrations.

[0067] Figure 2 shows the results of observing the protective effects of six types of natural extracts on R28 optic nerve cells using an MTT assay.

[0068] Figure 3 shows the results of confirming the synergistic effect on cell protection for a mixture of two extracts among perilla, rose, and peppermint extracts.

[0069] Figure 4 shows the results of confirming the synergistic effect on cell protection for perilla+rose and perilla+peppermint extract mixtures with different mixing ratios.

[0070] The present invention will be explained in more detail below through examples. The following examples are intended solely to explain the present invention more specifically, and it will be obvious to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention.

[0071]

[0072] Example 1. Preparation of natural product extract

[0073] Six types of natural products, such as yarrow (Achillea millefolium), rose (Rosa hybrida), perilla (Perilla frutescens), chamomile (Chamaemelum nobile), peppermint (Mentha piperita), and Agastache rugosa, were subjected to hot water extraction twice at 85°C for 30 minutes and concentrated using an evaporator to obtain natural product extracts.

[0074]

[0075] Example 2. Cell Culture and Preparation

[0076] R28 cells, which are optic nerve cells, were prepared by culturing them in DMEM medium (Dulbecco Modified Eagle Medium) containing low glucose, 10% fetal bovine serum (FBS), and 1% antibiotics (penicillin and streptomycin) at 37°C and 5% CO2.

[0077]

[0078] Example 3. DPPH Radical Scavenging Activity Analysis

[0079] Six types of natural product extracts were dissolved in methanol at concentrations of 0.01, 0.1, 1, and 10 μg / mL; 160 μL aliquots were then mixed with 40 μL of a DPPH solution dissolved in methanol and reacted. After standing the mixture at room temperature for 30 minutes, the absorbance was measured at 520 nm using a microreader. Free radical scavenging activity was expressed as a percentage compared to a control group without added samples, and the 50% scavenging concentration (IC10) was used. 50 ) calculated.

[0080]

[0081] Example 4. Analysis of optic nerve viability using MTT assay

[0082] Six types of natural extract samples were pretreated at concentrations of 3, 10, 30, and 100 μg / mL for 30 minutes. Subsequently, R28 optic neurons were treated with 0.5 mM hydrogen peroxide (H2O2) for 24 hours to induce apoptosis, after which cell viability was measured. Cell viability was confirmed via the MTT assay by measuring the absorbance of MTT to determine the extent to which formazan is formed by mitochondrial reductase in living cells. The control group (Control, CTL) was not treated with either the sample or H2O2, while the solvent control group (Veh) was treated with only H2O2.

[0083]

[0084] The effects of the present invention will be explained below through experimental examples. However, the effects of the present invention are not limited to the following experimental examples.

[0085]

[0086] Experimental Example 1. Confirmation of antioxidant efficacy of natural product extracts in optic nerve cells

[0087] Glaucoma is closely related to oxidative stress, and it is known that oxidative stress plays an important role in the onset and progression of glaucoma. Therefore, we wanted to determine whether six types of natural extracts (yarrow, rose, perilla, chamomile, peppermint, and Korean mint) have antioxidant efficacy.

[0088] Specifically, natural product extracts were prepared at different concentrations using the same method as in Example 3, and their DPPH radical scavenging ability was analyzed, and the results are shown in Figure 1.

[0089] As shown in Figure 1, the antioxidant efficacy of six natural extracts was analyzed using DPPH radical scavenging activity, and it was confirmed that the antioxidant efficacy was in the order of rose, perilla, peppermint, Korean mint, yarrow, and chamomile. (N>3, *p<0.05 vs. CTL)

[0090]

[0091] Experimental Example 2. Confirmation of cytoprotective effect of natural product extract in optic nerve cells

[0092] To confirm the neuroprotective effects of six types of natural extracts exhibiting antioxidant efficacy, R28 optic nerve cells were cultured as in Example 2, and the neuroprotective effects of the six types of natural extracts were observed using an MTT assay as in Example 4, and the results are shown in Figure 2.

[0093] As shown in Figure 2, it was confirmed that only Perilla frutescens, rose, and peppermint exhibited a cytoprotective effect of over 50% during the process of neuronal cell death induced by H2O2. (N>3, *p<0.05 vs. CTL, # p<0.05 vs. Veh)

[0094]

[0095] Experimental Example 3. Confirmation of synergistic cytoprotective effect of natural product extract complex in optic nerve cells

[0096] In Experimental Example 2, since no efficacy was observed in the single extracts of perilla, rose, and peppermint at 10 μg / mL each, a synergistic effect on cell protection was confirmed in the two mixtures based on the concentration at which no efficacy was observed, and the results are shown in Figure 3.

[0097] As shown in Figure 3, the protective effects on optic nerve cells were observed after treating the samples with a total of three groups: Perilla + Rose, Perilla + Peppermint, and Rose + Peppermint. As a result, synergistic efficacy of the mixture compared to the single extract was observed only in the Perilla + Rose and Perilla + Peppermint groups. (N>3, *p<0.05 vs. CTL, # p<0.05 vs. Veh)

[0098] Based on the results above, it was confirmed that a synergistic effect was observed only in the extract mixture containing perilla.

[0099]

[0100] Experimental Example 4. Confirmation of synergistic cell protection effects according to the mixing ratio of natural product extracts

[0101] Since a synergistic effect was observed for the mixtures of Perilla + Rose and Perilla + Peppermint extracts in Experimental Example 3, it was confirmed whether a synergistic effect of cell protection appeared by varying the mixing ratio of each extract, and the results are shown in Figure 4.

[0102] As shown in Figure 4, significant cytoprotective effects were observed for the perilla+rose and perilla+peppermint extract mixtures with different mixing ratios, confirming the synergistic efficacy of the mixture in cell protection compared to the single extract.

[0103] A composition for the prevention or treatment of retinal diseases or for improving eye health, comprising a Perilla frutescens extract according to one embodiment of the present invention and additionally comprising either a Rosa hybrida extract or a Mentha piperita extract, is based on natural materials, has few side effects, is accessible, and is economical, and has excellent eye health improvement effects; therefore, it can be usefully utilized for the prevention, treatment, or improvement of retinal diseases and for improving eye health, and thus has industrial applicability.

Claims

1. A pharmaceutical composition for the prevention or treatment of retinal disease comprising Perilla frutescens extract and additionally comprising either Rosa hybrida extract or Mentha piperita extract.

2. In Paragraph 1, A food composition for improving eye health, wherein the above extract is extracted using water, alcohol, or a mixture thereof as a solvent.

3. In Paragraph 1, A food composition for improving eye health, wherein the above extract is obtained by hot water extraction at a temperature of 70 to 90°C.

4. In Paragraph 1, The above composition comprises Perilla frutescens extract and Rosa hybrida extract, wherein the Perilla frutescens extract and Rosa hybrida extract are mixed in a weight ratio of 1:0.1 to 1, a food composition for improving eye health.

5. In Paragraph 1, The above composition comprises Perilla frutescens extract and Mentha piperita extract, wherein the Perilla frutescens extract and Mentha piperita extract are mixed in a weight ratio of 1:0.1 to 1, a food composition for improving eye health.

6. In Paragraph 1, A pharmaceutical composition for the prevention or treatment of retinal diseases, characterized in that the above-mentioned retinal disease is one or more selected from the group consisting of glaucoma, macular degeneration, retinal vascular occlusion, macular hole, diabetic retinopathy, retinal detachment, central serous retinopathy, night blindness, retinitis pigmentosa, epiretinal membrane, retinitis pigmentosa, optic neuropathy, and retinopathy.

7. A health functional food composition for the prevention or improvement of retinal diseases, comprising Perilla frutescens extract and additionally comprising either Rosa hybrida extract or Mentha piperita extract.

8. In Paragraph 7, A health functional food composition for the prevention or improvement of retinal diseases, characterized in that the above-mentioned retinal disease is one or more selected from the group consisting of glaucoma, macular degeneration, retinal vascular occlusion, macular hole, diabetic retinopathy, retinal detachment, central serous retinopathy, night blindness, retinitis pigmentosa, epiretinal membrane, retinitis pigmentosa, optic neuropathy, and retinopathy.

9. A food composition for improving eye health comprising Perilla frutescens extract and additionally comprising either Rosa hybrida extract or Mentha piperita extract.

10. A food additive for improving eye health comprising Perilla frutescens extract and additionally comprising either Rosa hybrida extract or Mentha piperita extract.

11. A quasi-drug composition for improving eye health comprising Perilla frutescens extract and additionally comprising either Rosa hybrida extract or Mentha piperita extract.

12. A feed composition for improving eye health comprising Perilla frutescens extract and additionally comprising either Rosa hybrida extract or Mentha piperita extract.

Images